Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer

Objective: p53 and p16(INK4) are the common and important tumor suppressor genes. Aberrant expression of p53 or p16 protein has been reported in various malignancies including lung cancer. Our aim was to investigate the association of p53 and p16 expression in resected non-small cell lung carcinoma...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cardio-thoracic surgery 2003-02, Vol.23 (2), p.221-228
Main Authors: Cheng, Yeung-Leung, Lee, Shih-Chun, Harn, Horng-Jyh, Chen, Cheng-Jueng, Chen, Jen-Chih, Yu, Cheng-Ping
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - mortality
Chi-Square Distribution
Cyclin-Dependent Kinase Inhibitor p16 - analysis
Female
Humans
Immonohistochemical analysis
Immunohistochemistry - methods
Lung Neoplasms - diagnosis
Lung Neoplasms - mortality
Male
Medical sciences
Middle Aged
Non-small cell lung cancer
p16
p53
Pneumology
Prognosis
Proportional Hazards Models
Survival Analysis
Tropical medicine
Tumor Suppressor Protein p53 - analysis
Tumors of the respiratory system and mediastinum
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: p53 and p16(INK4) are the common and important tumor suppressor genes. Aberrant expression of p53 or p16 protein has been reported in various malignancies including lung cancer. Our aim was to investigate the association of p53 and p16 expression in resected non-small cell lung carcinoma (NSCLC) and evaluated their correlation with clinocopathologic features and survival. Methods: p16 and p53 expression were detected by immunohistochemical analysis of 90 paraffin specimens of resected NSCLC, including 35 squamous cell carcinoma, 47 adenocarcinoma, and eight large cell carcinoma, between stages I and IV. The immunohistochemical study was performed using the labeled streptavidine–biotin method with anti-p53 and anti-p16 monoclonal antibodies. Results: Fifty-two (57.8%) and 36 (40%) of 90 patients revealed aberrant immunostaining for p53 (p53+) and p16 (p16+), respectively. While 19 cases (21.1%) showed abnormal immunoreactivity for both p16 and p53. (p53+/p16+). There was no correlation of p53 or p16 expression with the clinicopathologic features. The Kaplan–Meier survival analysis demonstrated that patients with p16+, p53+, late stages, and nodal or distal metastasis had poor survival status (P=0.006, 0.013,
ISSN:1010-7940
1873-734X
DOI:10.1016/S1010-7940(02)00749-2